Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses

Bibliography

• Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep 2010;125(Suppl 3):16-26
   PubMed Web of Science ®Google Scholar
• De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006;5(12):1015-25
   PubMed Web of Science ®Google Scholar
• Davies WL, Grunert RR, Haff RF, Antiviral activity of 1-adamantanamine (Amantadine). Science 1964;144:862-3
   PubMed Web of Science ®Google Scholar
• Nakai K, Takeda K, Kimura H, Obstructive acute renal failure related to amantadine intoxication. Am J Emerg Med 2009;27(3):371 e5-71 e7
   PubMedGoogle Scholar
• Smith JR. Oseltamivir in human avian influenza infection. J Antimicrob Chemother 2010;65(Suppl 2):ii25-33
   PubMed Web of Science ®Google Scholar
• Tumpey TM, Garcia-Sastre A, Mikulasova A, Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci USA 2002;99(21):13849-54
   PubMed Web of Science ®Google Scholar
• Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008;41(1):13-9
   PubMed Web of Science ®Google Scholar
• Yen HL, Herlocher LM, Hoffmann E, Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005;49(10):4075-84
   PubMed Web of Science ®Google Scholar
• Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009;69(18):2523-31
   PubMed Web of Science ®Google Scholar
• Hauge SH, Dudman S, Borgen K, Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009;15(2):155-62
   PubMed Web of Science ®Google Scholar
• Duwe S, Heider A, Braun C, Person-to-person transmission of oseltamivir-resistant influenza A/H1N1 viruses in two households; Germany 2007/08. J Clin Virol 2009;46(3):295-7
   PubMed Web of Science ®Google Scholar
• Hurt AC, Lowther S, Middleton D, Barr IG. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model. Antiviral Res 2010;87(3):361-6
   PubMed Web of Science ®Google Scholar
• Williamson JC, Pegram PS. Neuraminidase inhibitors in patients with underlying airways disease. Am J Respir Med 2002;1(2):85-90
   PubMedGoogle Scholar
• Masuda T, Shibuya S, Arai M, Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorg Med Chem Lett 2003;13(4):669-73
   PubMed Web of Science ®Google Scholar
• Castillo R, Holland LE, Boltz DA. Peramivir and its use in H1N1 influenza. Drug Today 2010;46(6):399-408
   PubMed Web of Science ®Google Scholar
• Guo CT, Sun XL, Kanie O, An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. Glycobiology 2002;12(3):183-90
   PubMed Web of Science ®Google Scholar
• Matrosovich M, Klenk HD. Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Rev Med Virol 2003;13(2):85-97
   PubMed Web of Science ®Google Scholar
• Landers JJ, Cao Z, Lee I, Prevention of influenza pneumonitis by sialic Acid-conjugated dendritic polymers. J Infect Dis 2002;186(9):1222-30
   PubMed Web of Science ®Google Scholar
• Totani K, Kubota T, Kuroda T, Chemoenzymatic synthesis and application of glycopolymers containing multivalent sialyloligosaccharides with a poly(L-glutamic acid) backbone for inhibition of infection by influenza viruses. Glycobiology 2003;13(5):315-26
   PubMed Web of Science ®Google Scholar
• Tsuchida A, Kobayashi K, Matsubara N, Simple synthesis of sialyllactose-carrying polystyrene and its binding with influenza virus. Glycoconj J 1998;15(11):1047-54
   PubMed Web of Science ®Google Scholar
• Matsubara T, Onishi A, Saito T, Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. J Med Chem 2010;53(11):4441-9
   PubMed Web of Science ®Google Scholar
• Malakhov MP, Aschenbrenner LM, Smee DF, Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006;50(4):1470-9
   PubMed Web of Science ®Google Scholar
• Ehrhardt C, Seyer R, Hrincius ER, Interplay between influenza A virus and the innate immune signaling. Microbes Infect 2010;12(1):81-7
   PubMed Web of Science ®Google Scholar
• Solorzano A, Webby RJ, Lager KM, Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol 2005;79(12):7535-43
   PubMed Web of Science ®Google Scholar
• Basu D, Walkiewicz MP, Frieman M, Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol 2009;83(4):1881-91
   PubMed Web of Science ®Google Scholar
• Smee DF, Hurst BL, Egawa H, Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemoth 2009;64(4):741-6
   PubMed Web of Science ®Google Scholar
• Kiso M, Takahashi K, Sakai-Tagawa Y, T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010;107(2):882-7
   PubMed Web of Science ®Google Scholar
• Wunderlich K, Mayer D, Ranadheera C, Identification of a PA-binding peptide with inhibitory activity against Influenza A and B virus replication. PLoS ONE 2009;4(10):e7517
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang CY, Yang ST, Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene. Biochem Biophys Res Commun 2009;390(3):421-6
   PubMed Web of Science ®Google Scholar
• Mickleburgh I, Geng F, Tiley L. Mesoionic heterocyclic compounds as candidate messenger RNA cap analogue inhibitors of the influenza virus RNA polymerase cap-binding activity. Antivir Chem Chemother 2009;19(5):213-18
   PubMedGoogle Scholar
• Hastings JC, Selnick H, Wolanski B, Tomassini JE. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother 1996;40(5):1304-7
   PubMed Web of Science ®Google Scholar
• Sidwell RW, Bailey KW, Wong MH, In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 2005;68(1):10-17
   PubMed Web of Science ®Google Scholar
• Nguyen JT, Hoopes JD, Le MH, Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010;5(2):e9332
   PubMed Web of Science ®Google Scholar
• Ludwig S. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother 2009;64(1):1-4
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Dudziak D, Dirmeier U, Active NF-kappaB signalling is a prerequisite for influenza virus infection. J Gen Virol 2004;85(Pt 8):2347-56
   PubMed Web of Science ®Google Scholar
• Kashyap AK, Steel J, Rubrum A, Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog 2010;6(7):e1000990
   PubMed Web of Science ®Google Scholar
• Oh HL, Akerstrom S, Shen S, An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J Virol 2010;84(16):8275-86
   PubMed Web of Science ®Google Scholar
• De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 2001;14(2):382-97
   PubMed Web of Science ®Google Scholar
• Sidwell RW, Allen LB, Khare GP, Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob Agents Chemother 1973;3(2):242-6
   PubMed Web of Science ®Google Scholar
• De Clercq E, Cools M, Balzarini J, Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob Agents Chemother 1991;35(4):679-84
   PubMed Web of Science ®Google Scholar
• De Clercq E, Descamps J, De Somer P, Holy A. (S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 1978;200(4341): UNKNOWN
   Web of Science ®Google Scholar
• de Clercq E, Montgomery JA. Broad-spectrum antiviral activity of the carbocyclic analog of 3-deazaadenosine. Antiviral Res 1983;3(1):17-24
   PubMed Web of Science ®Google Scholar
• Borchardt RT, Keller BT, Patel-Thombre U. Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J Biol Chem 1984;259(7):4353-8
   PubMed Web of Science ®Google Scholar
• De Clercq E. Antiviral and antitumor activities of 5-substituted 2′-deoxyuridines. Methods Find Exp Clin Pharmacol 1980;2(5):253-67
   PubMed Web of Science ®Google Scholar
• Hasobe M, McKee JG, Borcherding DR, Borchardt RT. 9-(trans-2′,trans-3′-Dihydroxycyclopent-4′-enyl)-adenine and -3-deazaadenine: analogs of neplanocin A which retain potent antiviral activity but exhibit reduced cytotoxicity. Antimicrob Agents Chemother 1987;31(11):1849-51
   PubMed Web of Science ®Google Scholar
• Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 2008;19(3):115-24
   PubMedGoogle Scholar
• De Clercq E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res 2007;75(1):1-13
   PubMed Web of Science ®Google Scholar
• Jesus DM, Costa LT, Goncalves DL, Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J Virol 2009;83(22):11477-90
   PubMed Web of Science ®Google Scholar
• Buller RM, Owens G, Schriewer J, Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004;318(2):474-81
   PubMed Web of Science ®Google Scholar
• Parker S, Siddiqui AM, Oberle C, Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies. Virology 2009;385(1):11-21
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Keith KA, Kern ER. In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiviral Res 2006;71(1):24-30
   PubMed Web of Science ®Google Scholar
• Charity JC, Katz E, Moss B. Amino acid substitutions at multiple sites within the vaccinia virus D13 scaffold protein confer resistance to rifampicin. Virology 2007;359(1):227-32
   PubMed Web of Science ®Google Scholar
• Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 2005;4(2):219-34
   PubMedGoogle Scholar
• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106(4):1154-63
   PubMed Web of Science ®Google Scholar
• Mike S, Harrison C, Coles B, Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006;(4):CD005247
   Google Scholar
• Martinelli V, Radaelli M, Straffi L, Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 2009;30(Suppl 2):S167-70
   PubMed Web of Science ®Google Scholar
• Deng L, Dai P, Ciro A, Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virol 2007;81(24):13392-402
   PubMed Web of Science ®Google Scholar
• De Clercq E. Emerging antiviral drugs. Expert Opin Emerg Drugs 2008;13(3):393-416
   PubMed Web of Science ®Google Scholar
• Bolken TC, Hruby DE. Tecovirimat for smallpox infections. Drugs Today (Barc) 2010;46(2):109-17
   PubMed Web of Science ®Google Scholar
• Chen Y, Peng C, Sullivan C, Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anticancer Agents Med Chem 2010;10(2):111-15
   PubMed Web of Science ®Google Scholar
• Reeves PM, Bommarius B, Lebeis S, Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005;11(7):731-9
   PubMed Web of Science ®Google Scholar
• Pytel D, Sliwinski T, Poplawski T, Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009;9(1):66-76
   PubMed Web of Science ®Google Scholar
• Yang HL, Kim SK, Kim M, Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005;115(2):379-87
   PubMed Web of Science ®Google Scholar
• Borio L, Inglesby T, Peters CJ, Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287(18):2391-405
   PubMed Web of Science ®Google Scholar
• Ascenzi P, Bocedi A, Heptonstall J, Ebolavirus and marburgvirus: insight the filoviridae family. Mol Aspects Med 2008;29(3):151-85
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Bausch DG, Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 2010;20(6):344-57
   PubMed Web of Science ®Google Scholar
• Barrientos LG, Gronenborn AM. The highly specific carbohydrate-binding protein cyanovirin-N: structure, anti-HIV/Ebola activity and possibilities for therapy. Mini Rev Med Chem 2005;5(1):21-31
   PubMed Web of Science ®Google Scholar
• Barrientos LG, Lasala F, Otero JR, In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins. J Infect Dis 2004;189(8):1440-3
   PubMed Web of Science ®Google Scholar
• Barrientos LG, O'Keefe BR, Bray M, Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res 2003;58(1):47-56
   PubMed Web of Science ®Google Scholar
• Lee JE, Saphire EO. Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol 2009;19(4):408-17
   PubMed Web of Science ®Google Scholar
• Lee JE, Saphire EO. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol 2009;4(6):621-35
   PubMed Web of Science ®Google Scholar
• Hartlieb B, Modrof J, Muhlberger E, Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem 2003;278(43):41830-6
   PubMed Web of Science ®Google Scholar
• Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008;78(1):26-36
   PubMed Web of Science ®Google Scholar
• Warfield KL, Swenson DL, Olinger GG, Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2006;2(1):e1
   PubMed Web of Science ®Google Scholar
• Enterlein S, Warfield KL, Swenson DL, VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother 2006;50(3):984-93
   PubMed Web of Science ®Google Scholar
• Swenson DL, Warfield KL, Warren TK, Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother 2009;53(5):2089-99
   PubMed Web of Science ®Google Scholar
• Warren TK, Warfield KL, Wells J, Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16(9):991-4
   PubMed Web of Science ®Google Scholar
• Fowler T, Bamberg S, Moller P, Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 2005;86(Pt 4):1181-8
   PubMed Web of Science ®Google Scholar
• Groseth A, Hoenen T, Alimonti JB, In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. J Infect Dis 2007;196(Suppl 2):S382-9
   PubMed Web of Science ®Google Scholar
• Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000;45(2):135-47
   PubMed Web of Science ®Google Scholar
• Huggins J, Zhang ZX, Bray M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis 1999;179(Suppl 1):S240-7
   PubMed Web of Science ®Google Scholar
• Vittori S, Dal Ben D, Lambertucci C, Antiviral properties of deazaadenine nucleoside derivatives. Curr Med Chem 2006;13(29):3529-52
   PubMed Web of Science ®Google Scholar
• Bray M, Raymond JL, Geisbert T, Baker RO. 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res 2002;55(1):151-9
   PubMed Web of Science ®Google Scholar
• Warren TK, Warfield KL, Wells J, Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010;54(5):2152-9
   PubMed Web of Science ®Google Scholar
• Kinch MS, Yunus AS, Lear C, FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res 2009;1(1):87-98
   PubMed Web of Science ®Google Scholar
• Aman MJ, Kinch MS, Warfield K, Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009;83(3):245-51
   PubMed Web of Science ®Google Scholar
• Spurgers KB, Alefantis T, Peyser BD, Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen. Mol Cell Proteomics 2010;9(12):2690-703
   PubMed Web of Science ®Google Scholar
• Charrel RN, de Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res 2003;57(1-2):89-100
   PubMed Web of Science ®Google Scholar
• Briese T, Paweska JT, McMullan LK, Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 2009;5(5):e1000455
   PubMed Web of Science ®Google Scholar
• Delgado S, Erickson BR, Agudo R, Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog 2008;4(4):e1000047
   PubMed Web of Science ®Google Scholar
• McKee KT Jr, Oro JG, Kuehne AI, Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques. Intervirology 1992;34(3):154-63
   PubMed Web of Science ®Google Scholar
• Maiztegui JI, McKee KT Jr, Barrera Oro JG, Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 1998;177(2):277-83
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004;10(12 Suppl):S110-21
   PubMed Web of Science ®Google Scholar
• McKee KT Jr, Huggins JW, Trahan CJ, Mahlandt BG. Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother 1988;32(9):1304-9
   PubMed Web of Science ®Google Scholar
• Perez M, Greenwald DL, de la Torre JC. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol 2004;78(20):11443-8
   PubMed Web of Science ®Google Scholar
• Cordo SM, Candurra NA, Damonte EB. Myristic acid analogs are inhibitors of Junin virus replication. Microbes Infect 1999;1(8):609-14
   PubMed Web of Science ®Google Scholar
• Strecker T, Maisa A, Daffis S, The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. Virol J 2006;3:93
   PubMed Web of Science ®Google Scholar
• Garcia CC, Topisirovic I, Djavani M, An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein. Biochem Biophys Res Commun 2010;393(4):625-30
   PubMed Web of Science ®Google Scholar
• Garcia CC, Ellenberg PC, Artuso MC, Characterization of Junin virus particles inactivated by a zinc finger-reactive compound. Virus Res 2009;143(1):106-13
   PubMed Web of Science ®Google Scholar
• Garcia CC, Djavani M, Topisirovic I, Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds. J Gen Virol 2006;87(Pt 5):1217-28
   PubMed Web of Science ®Google Scholar
• Sepulveda CS, Garcia CC, Damonte EB. Inhibition of arenavirus infection by thiuram and aromatic disulfides. Antiviral Res 2010;87(3):329-37
   PubMed Web of Science ®Google Scholar
• Artuso MC, Ellenberg PC, Scolaro LA, Inhibition of Junin virus replication by small interfering RNAs. Antiviral Res 2009;84(1):31-7
   PubMed Web of Science ®Google Scholar
• Bolken TC, Laquerre S, Zhang Y, Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res 2006;69(2):86-97
   PubMed Web of Science ®Google Scholar
• York J, Dai D, Amberg SM, Nunberg JH. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J Virol 2008;82(21):10932-9
   PubMed Web of Science ®Google Scholar
• Larson RA, Dai D, Hosack VT, Identification of a broad-spectrum arenavirus entry inhibitor. J Virol 2008;82(21):10768-75
   PubMed Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH, In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007;51(9):3168-76
   PubMed Web of Science ®Google Scholar
• Gowen BB, Smee DF, Wong MH, Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 2008;3(11):e3725
   PubMed Web of Science ®Google Scholar
• Rojek JM, Pasqual G, Sanchez AB, Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J Virol 2010;84(1):573-84
   PubMed Web of Science ®Google Scholar
• Ji WT, Liu HJ. PI3K-Akt signaling and viral infection. Recent Pat Biotechnol 2008;2(3):218-26
   PubMedGoogle Scholar
• Linero FN, Scolaro LA. Participation of the phosphatidylinositol 3-kinase/Akt pathway in Junin virus replication in vitro. Virus Res 2009;145(1):166-70
   PubMed Web of Science ®Google Scholar
• Vela EM, Bowick GC, Herzog NK, Aronson JF. Genistein treatment of cells inhibits arenavirus infection. Antiviral Res 2008;77(2):153-6
   PubMed Web of Science ®Google Scholar
• Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008;78(1):125-31
   PubMed Web of Science ®Google Scholar
• Koksal I, Yilmaz G, Aksoy F, The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010;47(1):65-8
   PubMed Web of Science ®Google Scholar
• Pittman PR, Liu CT, Cannon TL, Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 1999;18(1-2):181-9
   PubMed Web of Science ®Google Scholar
• Niklasson B, Peters CJ, Bengtsson E, Norrby E. Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. Vaccine 1985;3(2):123-7
   PubMed Web of Science ®Google Scholar
• Ikegami T, Makino S. Rift valley fever vaccines. Vaccine 2009;27(Suppl 4):D69-72
   PubMed Web of Science ®Google Scholar
• Wolf MC, Freiberg AN, Zhang T, A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA 2010;107(7):3157-62
   PubMed Web of Science ®Google Scholar
• Bouloy M, Weber F. Molecular biology of rift valley Fever virus. Open Virol J 2010;4:8-14
   PubMedGoogle Scholar
• Gowen BB, Wong MH, Jung KH, Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. Antiviral Res 2008;77(3):215-24
   PubMed Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH, Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 2010;86(2):121-7
   PubMed Web of Science ®Google Scholar
• Muranyi W, Bahr U, Zeier M, van der Woude FJ. Hantavirus infection. J Am Soc Nephrol 2005;16(12):3669-79
   PubMed Web of Science ®Google Scholar
• Gavrilovskaya IN, Shepley M, Shaw R, Beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci USA 1998;95(12):7074-9
   PubMed Web of Science ®Google Scholar
• Larson RS, Brown DC, Ye C, Hjelle B. Peptide antagonists that inhibit Sin Nombre virus and hantaan virus entry through the beta3-integrin receptor. J Virol 2005;79(12):7319-26
   PubMed Web of Science ®Google Scholar
• Hall PR, Malone L, Sillerud LO, Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem Biol Drug Des 2007;69(3):180-90
   PubMed Web of Science ®Google Scholar
• Xu R, Yang XY, Yang DF, Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers. Antimicrob Agents Chemother 2009;53(12):5055-9
   PubMed Web of Science ®Google Scholar
• Yang J, Chen R, Wei J, Production and characterization of a recombinant single-chain antibody against Hantaan virus envelop glycoprotein. Appl Microbiol Biotechnol 2010;86(4):1067-75
   PubMed Web of Science ®Google Scholar